Sunday, November 29, 2015 12:52:26 PM
I strongly urge you to do some DD. Specifically around the corp structure and relationships between the various parties. Look at the voting shares, look at who controls the patents and how they get compensated IF they ever get anything to market, and look at the company's history of developments and objectives and communication. Then look a the actual information that was released and by whom. Look at the former collaborators that are now no longer on the payroll and no longer interested in NNVC. Look at all the 'codes throughout the years that had "laser like" focus, only to be replaced with another "flavor of the month." There is a pattern and a reason for this continual repetitive cycle. Read this board from the past 5 years, search something like Tox or clinicals or Dengue and see how we are hearing the exact same claims.
In my opinion (and I have been correct for 4 years) there will be no Tox in '16, no clinicals in '16 and no scale up completed in '16. And use Occam's razor and it is clear why that will occur.
May I ask, if that is the case, and I am once again correct, and we are chatting in 12 months, how confidant will you be in the company? I ask because there are many here who were also previous longs and bulls and now are not. History is a great teacher for those who are smart enough to listen.
Good Luck. Let's catch up again in 12 months.
Recent NNVC News
- Form 8-K - Current report • Edgar (US Regulatory) • 08/09/2024 08:30:39 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 08/09/2024 08:05:25 PM
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
Lingerie Fighting Championships Signs Broadcast Deal With Maybacks Global Entertainment • BOTY • Sep 26, 2024 9:00 AM
Maybacks Global Entertainment and Lingerie Fighting Championships Enter Into Broadcast And Revenue Sharing Agreement • AHRO • Sep 26, 2024 8:30 AM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM